Decision analysis of prophylactic mastectomy and oophorectomy in BRCA1- positive or BRCA2-positive patients

Journal of Clinical Oncology

Volumn 16, Issue 3, 1998, Pages 979-985

  Grann, Victor R ^a   Panageas, Katherine S ^a   Whang, William ^a   Antman, Karen H ^a   Neugut, Alfred I ^a  

^a School of Public Health ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BREAST CANCER; CANCER PREVENTION; CANCER RISK; CANCER SURVIVAL; COST BENEFIT ANALYSIS; GENE MUTATION; GENETIC RISK; MASTECTOMY; MODEL; OVARIECTOMY; OVARY CANCER; PRIORITY JOURNAL; QUALITY OF LIFE; RISK ASSESSMENT;

EID: 0031931894     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1998.16.3.979     Document Type: Article

References (29)

1. Miki Y, Swensen J, Shattuck-Eiders D, et al: Isolation of BRCA1, the 17q-linked breast and ovarian cancer susceptibility gene. Science 266:66-71, 1994
2. Easton DF, Ford D, Bishop T, and the Breast Cancer Linkage Consortium: Breast and ovarian cancer incidence in BRCA1 mutation. Am J Hum Genet 56:265-267, 1995
3. Wooster R, Bignell G, Lancaster J, et al: Identification of the breast cancer susceptibility gene BRCA2. Nature 378:789-792, 1995
4. Struewing JP, Hartge P, Wacholder S, et al: The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenzai Jews. N Engl J Med 336:1401-1408, 1997
5. Burke W, Daly M, Garber J, et al: Recommendations for follow-up care of individuals with an inherited predisposition to cancer II. BRCA1 and BRCA2. JAMA 277:997-1003, 1997
6. Beck JR, Pauker SG: The Markov process in medical prognosis. Med Decis Making 3:419-458, 1983
7. Schrag D, Kuntz KM, Garber JE, et al: Decision analysis-effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. New Engl J Med 336:1465-1471, 1997
8. Ford D, Easton DR, Peto J: Estimates of the gene frequency of BRCA1 and its contribution to breast and ovarian cancer incidence. Am J Hum Genet 57:1457-1462, 1995
9. Kosary DL, Ries LAG, Miller BA, et al (eds): SEER cancer statistics review, 1973-1992: Tables and graphs. Bethesda, MD, National Cancer Institute, 1995, NIH 96-2789
10. Johannsson O, Ranstam J, Borg A, et al: BRCA1 mutations and survival in women with ovarian cancer. New Engl J Med 336:1255-1256, 1997 (letter)
11. Brunet J, Narod S: BRCA1 mutatons and survival in women with ovarian cancer. New Engl J Med 336:1256, 1997 (letter)
12. Rubin SC, Benjamin I, Behbakut K, et al: Clinical and pathological features of ovarian cancer in women with germ-line mutations of BRCA1. New Engl J Med 33:1413-1416, 1996
13. Struewing JP, Watson P, Easton DF, et al: Prophylactic oophorectomy in inherited breast/ovarian cancer families. Natl Cancer Inst Monogr 17:1529-1533, 1995
14. Hartman L, Jenkins R, Schaid D, et al: Prophylactic mastectomy (PM): Preliminary retrospective cohort analysis. Proc Am Assoc Cancer Res 38:1123, 1997 (abstr)
15. Ziegler LD, Kroll SS: Primary breast cancer after prophylactic mastectomy. Clinical case reports from MD Anderson Cancer Center. Clin Oncol 14:451-454, 1991
16. Health Care Financing Administration: Bureau of data management and strategy from the 100% medpar inpatient hospital fiscal year 1994: All inpatient by diagnosis related groups, 6/95 update. Http:// www.hcfa.gov/a1194drg.txt
17. Cardinale V (ed): Drug Topics Red Book, Pharmacy Fundamental Reference. Montvale, NJ, Medical Economics, 1996
18. Gold MR, Siegel JE, Russel LB, et al (eds): Cost-Effectiveness in Health and Medicine. New York, NY, Oxford University Press, 1996
19. Ashby J, O'Hanlon M, Buxton MJ: The time trade-off technique: How do the valuations of breast cancer patients compare to those of other groups? Qual Life Res 3:257-265, 1994
20. Hall J, Gerard K, Salkfeld G, et al: A cost utility analysis of mammography screening in Australia. Soc Sci Med 34:993-1004, 1992
21. Hilner BE, Smith TJ: Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. New Engl J Med 324:160-168, 1991
22. Erickson P, Wilson R, Shannon I: Years of Healthy Life. Statistical Notes No. 7, April 1995, pp 1-14
23. Lynch HT, Bewtra C, Lynch JF: Familial peritoneal ovarian carcinomatosis: A new clinical entity? Med Hyp 21:171-177, 1986
24. Barber HRK: Prophylaxis in ovarian cancer. Cancer 71:1529-1533, 1993
25. Berry DA, Parmigiani G, Sanchez J, et al: Probability of carrying a mutation of breast-ovarian cancer gene BRCA1 based on family history. J Natl Cancer Inst 89:227-238, 1997
26. Phelan CM, Rebbeck TR, Weber BL, et al: Ovarian cancer risk in BRCA1 carriers is modified by the HRAS1 variable number of tandem repeat (VNTR) locus. Nature Genetics 12:309-310, 1996
27. Hillner BE, Smith TJ, Desch CE: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer, estimates using decision analysis while awaiting clinical trial results. JAMA 267:2055-2061, 1992
28. Kolata G: Advent of testing for breast cancer genes leads to fears of disclosure and discrimination. New York Times Feb 4, 1997, C1
29. Grann VR, Panageas K, Whang W: A decision analysis of prophylactic surgery in patients positive for the BRCA1 gene test. Proc Am Soc Clin Oncol 16:1981, 1997 (abstr)